SCHEMBL4694050

SCHEMBL4694050

Clc1cncc(N2CCSCC2)n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.64
ALDH1A1 P00352 2/20 0.64
KDM4E B2RXH2 1/20 0.64
MEN1 O00255 1/20 0.64
CYP1A2 P05177 1/20 0.64
CYP3A4 P08684 1/20 0.64
HTR1A P08908 1/20 0.64
CYP2C9 P11712 1/20 0.64
HPGD P15428 1/20 0.64
HTR2A P28223 1/20 0.64
HTR2C P28335 1/20 0.64
CYP2C19 P33261 1/20 0.64
HSD17B10 Q99714 1/20 0.64
CNR2 P34972 1/20 0.39
CDK2 P24941 1/20 0.36
POLB P06746 1/20 0.36
HTR3E A5X5Y0 2/20 0.35
HTR3B O95264 2/20 0.35
HTR3A P46098 2/20 0.35
HTR3D Q70Z44 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL939716 0.82 ALDH1A1 (0.70) KMT2AALDH1A1KDM4EMEN1CYP1A2
SCHEMBL31558499 0.81 CYP1A2 (0.68) KMT2AALDH1A1KDM4EMEN1CYP1A2
SCHEMBL19673985 0.81 CYP1A2 (0.68) KMT2AALDH1A1KDM4EMEN1CYP1A2
SCHEMBL1713569 0.79 ALDH1A1 (0.66) KMT2AALDH1A1KDM4EMEN1CYP1A2
Mk-212 SCHEMBL255453 0.78 HTR2A (1.00) KMT2AALDH1A1KDM4EMEN1CYP1A2
SCHEMBL3089415 0.78 KMT2A (0.64) KMT2AALDH1A1KDM4EMEN1CYP1A2
SCHEMBL3056725 0.78 KDM4E (0.64) KMT2AALDH1A1KDM4EMEN1CYP1A2
Mk-212 SCHEMBL29389957 0.78 HTR2A (1.00) KMT2AALDH1A1KDM4EMEN1CYP1A2
Hydrochloric Acid SCHEMBL11557145 0.76 KDM4E (0.62) KMT2AALDH1A1KDM4EMEN1CYP1A2
Mk-212 SCHEMBL3060615 0.76 HTR2A (0.96) KMT2AALDH1A1KDM4EMEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1871762-A2 SUBTITUTED HETEROARYL CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2008-01-02 EP disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
WO-2006113704-A2 SUBTITUTED HETEROARYL CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078135-A1 Substituted heteroaryl CB1 antagonists CNR1, CNR2, OPRL1 KMT2A 1771/4885ALDH1A1 1492/4885KDM4E 1408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.